Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 96 Pancreatic Neoplasms 85 Carcinoma, Non-Small-Cell Lung 79 Ovarian Neoplasms 52 Fallopian Tube Neoplasms 48 Triple Negative Breast Neoplasms 42 Lung Neoplasms 32 Neoplasm Metastasis 27 Squamous Cell Carcinoma of Head and Neck 23 Neoplasms 19 Breast Neoplasms, Male 18 Endometrial Neoplasms 17 Uterine Cervical Neoplasms 16 Stomach Neoplasms 16 Melanoma 16 Brenner Tumor 16 Carcinoma, Ovarian Epithelial 15 Esophageal Neoplasms 14 Adenocarcinoma of Lung 13 Inflammatory Breast Neoplasms 11 Cholangiocarcinoma 10 Adenocarcinoma, Bronchiolo-Alveolar 9 Urinary Bladder Neoplasms 8 Unspecified Adult Solid Tumor, Protocol Specific 8 Oropharyngeal Neoplasms 8 Carcinoma, Transitional Cell 8 Adenocarcinoma Of Esophagus 8 Mouth Neoplasms 7 Colorectal Neoplasms 7 Adenocarcinoma 7

Interventions

Nivolumab 3 Cisplatin 2 Albumin-Bound Paclitaxel 2 tislelizumab 1 spartalizumab 1 Taxes 1 Standard of Care 1 Radiotherapy 1 Neoadjuvant Therapy 1 Immunotherapy 1 Gemcitabine 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Muscle-Invasive Bladder Carcinoma × Taxes × Clear all

NCT05203913 2024-10-04

CNN-BC

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 2 Recruiting

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡